- Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer. [Editorial]Ann Oncol. 2026 Jul 10. [Online ahead of print]AO
- Publisher Full Text (DOI)
- Measurement of Ovarian Reserve to Tailor Systemic Therapy Decisions: Future Potential or Ready for Primetime? [Editorial]Ann Oncol. 2026 Jul 09. [Online ahead of print]AO
- Publisher Full Text (DOI)
- HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap. [Editorial]Ann Oncol. 2026 Jul 07. [Online ahead of print]AO
- Publisher Full Text (DOI)
- The ethical obligation to use positive trial results. [Letter]Ann Oncol. 2026 Jun 27. [Online ahead of print]AO
- Publisher Full Text (DOI)
- Lorlatinib: The Crown Jewel of ALK Inhibitors. [Editorial]Ann Oncol. 2026 Jun 26. [Online ahead of print]AO
- Publisher Full Text (DOI)
- TROP2-directed antibody-drug conjugates: new first-line treatment for all patients with advanced triple-negative breast cancer? [Editorial]Ann Oncol. 2026 Jun 25. [Online ahead of print]AO
- Publisher Full Text (DOI)
- When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology. [Editorial]Ann Oncol. 2026 Jul; 37(7):886-888.AO
- Publisher Full Text (DOI)
- PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block? [Editorial]Ann Oncol. 2026 Jul; 37(7):877-879.AO
- Publisher Full Text (DOI)
- Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic. [Editorial]Ann Oncol. 2026 Jul; 37(7):873-876.AO
- Publisher Full Text (DOI)
- Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward. [Editorial]Ann Oncol. 2026 Jun 24. [Online ahead of print]AO
- Publisher Full Text (DOI)
- SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. [Journal Article]Ann Oncol. 2026 Jun 20. [Online ahead of print]AO
- CONCLUSIONS: Addition of pembrolizumab to SG did not significantly improve outcomes in HR+/HER2- MBC unselected by PD-L1. In the PD-L1-positive population, the trend in PFS and OS favoring SG+pembrolizumab warrants further investigation in larger randomized trials.
- Publisher Full Text (DOI)
- Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial. [Journal Article]Ann Oncol. 2026 Jun 17. [Online ahead of print]AO
- CONCLUSIONS: Among patients with heavily pretreated and immunotherapy-exposed recurrent or metastatic NPC, becotatug vedotin significantly improved ORR and PFS compared with chemotherapy, with comparable toxicity and encouraging but immature OS results.
- Publisher Full Text (DOI)
- ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word. [Editorial]Ann Oncol. 2026 Jun 11. [Online ahead of print]AO
- Publisher Full Text (DOI)
- Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation. [Journal Article]Ann Oncol. 2026 Jun 10. [Online ahead of print]AO
- CONCLUSIONS: Directed prompting during head and neck tumor board improved generated summaries, without increasing discussion times. Compared with manual documentation, ambient AI improved documentation quality, while diminishing administrative burden.
- Publisher Full Text (DOI)
- GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. [Journal Article]Ann Oncol. 2026 Jun 07. [Online ahead of print]AO
- CONCLUSIONS: GLP-1RA use was associated with a significantly lower short-term incidence of OACs among obese, nondiabetic patients, with consistent results observed in subgroups, except for race. Prospective trials are needed to confirm causality.
- Publisher Full Text (DOI)